LUDWIG ENTERPRISES - LUDG STOCK NEWS

Ludwig Enterprises, Inc. has received Continuing Review Approval from Advarra IRB for its planned clinical study, LL301, focused on evaluating pre- and post-diagnosis and treatment response of patients with Urothelial Carcinoma of the Bladder. The study also includes potential breakthrough genetic results in BCG treatment of bladder cancer, covered in a filed international patent application. CEO Marvin S. Hausman MD expressed excitement for the study's launch and the creation of a personalized patient genetic index to evaluate patient response to BCG immunotherapy.

Ludwig Enterprises, Inc (OTC:LUDG) announces subsidiary Exousia AI's contract with Eternapure LLC for Liposome delivery system research and development. The company aims to develop cargo delivery platforms containing genetic mRNA and DNA, and nutritional compounds. CEO Marvin S. Hausman MD expresses positivity for the research program, with plans for additional similar arrangements.

Ludwig Enterprises, Inc. (LEI) Announces Appointment of Scott Silverman as Chief Financial Officer (CFO)

Ludwig Enterprises, Inc. (LUDG) - SEC Declares Registration Statement Effective, Seeking to Raise $23.5M through Common Stock Offering

Marvin S. Hausman MD joins Ludwig Enterprises as CEO, expressing excitement about the potential of their mRNA technology to save lives and lower healthcare budgets.

Ludwig Enterprises, Inc. (OTC:LUDG) has unveiled its marketing strategy for the new nutraceutical, NuGenea, aimed at combating chronic inflammation—a key contributor to major illnesses like cancer and heart disease. Formulated with 20 scientifically validated ingredients, NuGenea represents a significant advancement in health and wellness. Chief Marketing Officer, Luke Fannon, announced a multifaceted approach, targeting both consumers and healthcare professionals through digital advertising and retail placements. Pre-orders are available for interested consumers. The company leverages proprietary mRNA genomic technology through its subsidiary, Precision Genomics, paving the way for early disease detection and personalized treatment options, potentially transforming healthcare.

Ludwig Enterprises, Inc. (OTC PINK:LUDG) announced the upcoming launch of its nutraceutical NuGenea™, designed to combat chronic inflammation. This product is formulated with 20 scientifically tested ingredients that may impact mRNA biomarkers linked to inflammation, as highlighted by creator Dr. Marvin S. Hausman MD. The World Health Organization estimates that 50% to 60% of global deaths are linked to chronic inflammation-related diseases. Ludwig's subsidiary Precision Genomics developed the mRNA Inflammatory Index™, a tool for monitoring 48 mRNA biomarkers of inflammation. NuGenea will be sold directly to consumers through an upcoming website. The company aims to transform healthcare with its genomic technology, potentially preventing serious health issues and reducing costs in the healthcare sector. For more information, visit Ludwig's website.